Abstract Body

Background: Sequence variation is a major obstacle to developing molecular based assays for multiple subtypes. This study sought to independently assess performance characteristics of the ViroSeq™ HIV-1 Integrase RUO Genotyping Kit (Celera, US) for samples of multiple different subtypes. Methodology: 157 samples were used in the validation, 105 from integrase inhibitor naive patients’ plasma samples sent for routine HIV-1 drug resistance testing after failing a 1st- or 2nd-line regimen, and 52 from an external virology quality assurance program (VQA). 15 identical VQA samples were tested in two different laboratories to assess assay reproducibility. Viral RNA was extracted using the ViroSeq extraction module and reverse transcribed and amplified in a one-step reaction. Four sequencing primers were used to span codons 1-288 of integrase. The Rega subtyping tool was used for subtype assignment. Integrase polymorphisms and mutations were determined as differences from the HXB2 sequence and the Stanford database, respectively. Sequences obtained from the two laboratories were aligned and sequence homology determined. Results: HIV-1 RNA in the 157 samples ranged from 3.15 to 6.74logcopies/ml. Successful amplification was obtained for 95% of samples (n=149). The 8 samples that failed to amplify were subtype D (n=3), subtype C (n=1), CRF02_AE (n=1), subtype A (n=2), and unassigned subtype (n=1). Of the 149 successfully amplified samples, 126 (79%) were successfully sequenced with bidirectional coverage. Of the 23 unsuccessful samples, 12 (8%) failed sequencing and 11 (7%) did not have full bidirectional sequence, a result of failure of sequencing primers Primer A (n=1); Primer B (n=4); Primer C (n=2) and Primer D (n=6). For the 15 VQA samples that were sequenced in the two different laboratories, homology of the sequences obtained ranged from 99.01% to 100%. However, Lab 2 detected 23 mixtures; whereas Lab 1 only detected 9 mixtures in the 11219 nucleotide analysed, possibly due to differences between the labs in the methods of sequence analysis. Mutations associated with integrase resistance were observed in seven of the 137 (5%) samples [Q148K; E138K; G140A (n=1)], T97A (n=2), L74I (n=4). Of the four samples with L74I, 3 were subtype G. Conclusions: Of the 157 samples tested, 79% (n=126) were successfully amplified and a bi-directional sequence obtained. Sequencing results were similar between two testing laboratories with the exception of mixture detection. Mutations associated with integrase inhibitor resistance were observed in only 5% of integrase inhibitor naive samples, and some of these mutations are likely to be due to subtype specific polymorphisms rather than selection by an integrase inhibitor.